- Hirschhorn: Risk-Averse Traders
- Roginsky: A Funny Thing Happened on the Way to Financial Reform
- Downturn is Prime Time for Airport Infrastructure Projects
- Busch: Pressure Builds and Expands For Chinese Trade War
- Tamminen: Carbon Insurance For Your Car May Be Down The Road
- Busch: Another Obama Opportunity
- Farrell: Retailers?
- Schork: Nat Gas Bulls Need a Snow Day
- Schork Oil Outlook: Nat Gas Bulls Didn’t Stand A Chance
- Farr: An Extended Period—No Fat Lady in Sight
MOST SHARED
- Seeking Innovation in Health Care
- Today's Market Action
- Microsoft's Bill Gates Praises Apple's Steve Jobs For 'Saving the Company'
- Israel: Leader of Business Innovation
- Inside Wal-Mart's Acai Berry Juice Maker
- Low Interest Rate Investing
- Herbalife Vs. Hedge Funds
- Novo Nordisk CEO on Diabetes Epidemic
- Warren Buffett and Bill Gates: Keeping America Great
- Week Ahead: Investors Go for Quality, Assess Recovery
- Dollar is Not Plunging—So 'Calm Down': Market Strategist
- Strategists Say Markets Have More Upside — But How Much?
- Hirschhorn: Risk-Averse Traders
- Roginsky: A Funny Thing Happened on the Way to Financial Reform
- This Year's Biggest Thanksgiving Leftover: Cash
- TV Series Inks Unique Deal For Fight
- First Time Buyers Rescue Housing: Realtors
- Dollar General Trades Higher After Its IPO
- Fed Reform? Not So Fast.
- Oil Next Week: What Traders Will Be Watching
- Hedge Fund Billionaire Paulson Reports New Citi Stake
- Cramer: 5 Earnings Reports to Watch Next Week
- Court Rejects 'Clawbacks' for Alleged Stanford Victims
- Tax Credit Sparking First-Time Home Sales: Realtors
- Investors Cut Back US Stocks for Bigger Growth Abroad
- Cities With the Most Home Price Reductions
- White House Plans to Freeze Spending to Cut Deficit
- This Year's Biggest Thanksgiving Leftover: Cash
- Oil Next Week: What Traders Will Be Watching
RSS FEED
CNBC Guest Blog
Text Size 
I had a visit on "Power Lunch" today and we talked about the effect on the health care stocks depending on who wins the White House. In general, pharmaceutical companies do well when they have a new product pipeline of innovative products that allow them to command high prices. That is not the case now with the traditional health care equities so the direction of the political scene is even more important. Innovative products are coming from the biotech industry and that would be a fertile ground to investigate.
Expect significant pricing pressure on the health care industry if the Democrats control the office. More mandated enrollment in Medicare type programs will give the government additional levers to extract lower prices. That might be good and necessary, but it will hurt profit margins and returns on equity on the companies. Humana [HUM
Loading...
()
] might have a tough time with a large exposure in this area, and a United Healthcare [UAHC
Loading...
()
] might fare somewhat better with a more diversified business.
The issue of drug reimportation will probably arise and that won't be good for the basic pharma companies. Along with tougher negotiations on drug costs, the pharma companies might be unattractive for a while. At some price, all potential negatives will be discounted, but when now Senator Clinton launched a health care initiative during her husband's first term, this group traded to a significant discount to the market as the fear of pricing pressure drove investors away.
A traditional response to a Republican in the White House would be much the opposite of the above. There would be less pricing pressure and many of the stocks would prove to be at attractive levels now.
I'm not willing to go too far out on a limb with this industry with the election still months away. At Scotsman Capital, we have concentrated our holdings to a few names. JNJ [JNJ
Loading...
()
] is a world class company with a diverse business. It's trading at 14x the consensus estimate for this year and that is at the very low end of its historical valuation range, and slightly below a market multiple. Becton Dickinson in the instrumentation area is our other choice. It's at 17x this years estimate, which is not cheap, but we think represents very sound value relative to its growth prospects. I own both names personally. _______________________________________
Vincent Farrell, Jr. is a Principal of Scotsman Capital Management and a regular contributor CNBC. 
Data is a real-time snapshot *Data is delayed at least 15 minutes